CooperCompanies (NASDAQ: COO), a leading medical device company, saw its stock plunge 7.95% in after-hours trading on Thursday, March 6, despite reporting solid fiscal first-quarter 2025 results and raising its full-year guidance.
For the quarter ended January 31, 2025, CooperCompanies delivered a 4% year-over-year increase in revenue to $964.7 million, with its CooperVision segment growing 6% organically and CooperSurgical segment up 2% organically. Non-GAAP diluted earnings per share came in at $0.92, up from $0.85 in the prior-year period.
Encouraged by the strong start to the fiscal year, the company raised its full-year 2025 non-GAAP EPS guidance to a range of $3.94 to $4.02, up from its previous outlook of $3.92 to $4.02. Management commented on their confidence in delivering robust growth and operational excellence going forward.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.